Immuneering financials at a glance

+ Portfolio

The revenue of Immuneering is reported as 0 billion Dollars in the fiscal year 2023. The earnings were -1.88 Dollars per share in 2023, which was 22.36 higher than 2021. And about -0.05044 billion Dollars are reported as free cash flow in the financials of Immuneering 2023. No dividends were paid to the shareholders of the Immuneering stock NasdaqGM:IMRX in the financial year 2023.

$0.32M

Revenue

$-1.91

Earnings Per Share

50.11%

Gross Margin %

$0.00M

Free Cash Flow

Revenue

0.32

Earnings Per Share

-1.91

Gross Margin %

50.11

Free Cash Flow

0.00

Financials

Year	Year	TTM	2022	2021
Rev.	Revenue	N/A	$0.32M	$2.08M
GM %	Gross Margin %	100.00%	50.11%	44.56%
OM	Operating Margin	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-1.86	$-1.91	$-2.46
Div.	Dividends	N/A	$0.00	$0.00
PR %	Payout Ratio %	0	0	0
Sha.	Shares	N/AM	26.44M	26.38M
OCF	Operating Cash Flow	N/A	$0.00M	$0.00M
FCF	Free Cash Flow	N/A	$0.00M	$0.00M
FCFS	Free Cash Flow Per Share	$-1.78	$-1.70	$-2.27

Immuneering financials at a glance

Financials

Discover